Trial Condition(s):
Pulmonary hypertension
Observational study on residual disease in chronic thromboembolic pulmonary hypertension following pulmonary endarterectomy
Bayer Identifier:
20565
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
Trial Purpose
Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension caused by obstruction of the pulmonary vasculature by thromboembolic material and is potentially curable by pulmonary endarterectomy (PEA) surgery. However, in some cases patients may experience recurrent or persistent (residual) disease following PEA.
The proposed study will describe the rates of symptoms and diagnostic procedural claims related to residual disease in CTEPH patients over a two year period following PEA.
The results may help to identify potential gaps in care and to raise awareness of the need to follow-up and screen at risk post-PEA patients for residual disease.
Inclusion Criteria
- Adults patients ≥ 18 years of age on the index date - One claim of pulmonary endarterectomy (PEA) following a claim of pulmonary hypertension (PH) or chronic thromboembolic pulmonary hypertension (CTEPH) - ≥ 730 days continuous enrollment post-PEA
Exclusion Criteria
- Patients under the age of 18 - Patients with < 730 days of continuous enrollment following the index date
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | Status | ||
|---|---|---|---|
Locations Multipal locations Cleveland, United States, 44195 | Status Completed | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Trial Design
Residual disease in CTEPH following PEA
Trial Type:
Observational
Intervention Type:
Diagnostic Test
Trial Purpose:
Other
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- The number of patients with recorded symptoms indicative of residual CTEPH, and the proportion of these patients who undergo diagnostic assessmentsChronic thromboembolic pulmonary hypertension (CTEPH)Timeframe: Two years
Additional Information
Copyright © Bayer
Powered by
